Ms. Suzanne Osborne, Director of Clinical Support Terumo Cardiovascular , (centre) shared her perfusion expertise with clinicians across the Asia-Pacific Region during the week-long Patient Safety Roadshow

Delivering Value through Safety Education

Terumo Asia Pacific launched its first regional Patient Safety Roadshow in February, and welcomed Suzanne Osborne, Director of Clinical Support, USA, as the keynote speaker. The Roadshow took place in Thailand, Indonesia and the Philippines from February 16-23, 2023, and was aimed at demonstrating how TCV solutions help with perfusion and patient safety, as well as improving patient outcomes. The event received high marks from the more than 120 perfusionists who participated in hands-on simulations.

“As we continue to fulfill our Vision to be the most trusted provider of cardiovascular technologies, we are providing education programs that meet clinicians’ needs,” says Amy Peng, Regional Marketing Manager and Roadshow organizer. “We want to support perfusionist skill development and help them practice safe cardiopulmonary bypass procedures.”

The Roadshow also provided an opportunity to hear from customers about ideas for improving existing products that can lead to better patient safety. During roundtable discussions, perfusionists shared and learned from one another’s experiences to improve their practices.

“Improving patient outcomes is a key to our mission of saving lives. Through simulation, collaboration and training, I was able to show how our products can improve the lives of our patients,” says Suzanne. “It was an honor to speak to so many practicing clinicians across the region and see how their practices are very similar to ours in the US. Collaboration with our global practicing clinicians enables us at Terumo Cardiovascular to innovate and really understand what the needs of patients and clinicians are around the world.”

 

 

About Terumo Cardiovascular
Terumo Cardiovascular manufactures and markets medical devices for cardiac and vascular surgery with an emphasis on cardiopulmonary bypass and intra-operative monitoring. The company is headquartered in Ann Arbor, Michigan, with manufacturing operations in the U.S., Europe, Asia, and Latin America. It is one of several subsidiaries of Terumo Corporation of Japan that is focused exclusively on cardiovascular surgery specialties. For more information, visit www.terumocv.com

 

ANN ARBOR, MICH. – August 29, 2022 – Terumo Cardiovascular, a global leader in cardiovascular surgery technologies, is celebrating the 40th anniversary of its industry-leading Capiox brand of oxygenators. This remarkable milestone is unmatched in the global oxygenator category.

Terumo’s Capiox oxygenators and their unique combination of lifesaving, leadership, and technology has made them an industry leader for 40 years. Since the launch of the product line in 1982, Capiox oxygenators have become a global standard in patient care.

“In 1982, Terumo introduced the Capiox II oxygenator, the world’s first hollow fiber oxygenator, and has led the market in innovation ever since,” said Charlene Dusack, Senior Director, Global Marketing. “Through these 40 years, each successive product introduction in the Capiox line has focused on two critical aspects of an oxygenator – offering high performance for the operator and better outcomes for the patient.”

During their rich 40-year history, Terumo’s Capiox oxygenators have made a profound impact on healthcare. More than 2 million Capiox oxygenators have been manufactured to support critically ill heart patients around the world. Over the past four decades Capiox technology has continued to evolve and improve, with seven different families of oxygenators introduced to the marketplace. This legacy of innovation continues, with new Capiox technology in development and additional product launches planned for the future.

 

About Terumo Cardiovascular
Terumo Cardiovascular manufactures and markets medical devices for cardiac and vascular surgery with an emphasis on cardiopulmonary bypass and intra-operative monitoring. The company is headquartered in Ann Arbor, Michigan, with manufacturing operations in the U.S., Europe, Asia, and Latin America. It is one of several subsidiaries of Terumo Corporation of Japan that is focused exclusively on cardiovascular surgery specialties. For more information, visit www.terumocv.com

 

TOKYO, JAPAN — March 1, 2022 — Terumo Corporation (TSE: 4543) today announced that it has established a global “DE&I Philosophy” to further cultivate the culture of Diversity, Equity, and Inclusion (DE&I) at the Terumo Group. Additionally, a “DE&I Guiding Principle” has also been defined to ingrain DE&I norms of behavior in policies, processes, and day-to-day work practices.

Terumo provides medical products and solutions in more than 160 countries and regions. Currently, about 70% of the company’s revenue is generated outside of its corporate headquarters in Japan*1 and out of the 26,000 Terumo Group associates spread across the world, nearly 80% work outside of Japan.*2 Terumo believes it is most important for associates to respect and value differences as well as to empower everyone to bring their authentic self to work, in order to bring about innovation which will lead to the company’s continued growth.

To create the DE&I Philosophy and DE&I Guiding Principle, associates from various backgrounds in nationality, job, and generation formed a “Global DE&I Council.” The DE&I Philosophy and the DE&I Guiding Principle are aligned with Terumo’s Core Values and the Terumo Group Code of Conduct and clearly state the commitment to cultivate a globally diverse, equitable, and inclusive culture.

Furthermore, to celebrate and appreciate DE&I at the workplace, a “Terumo DE&I Week” will be carried out for all associates around the world to join. This year, various activities will be held from March 7 to 11; such as video messages from the management team, online DE&I panel discussion, as well as local events at each Group company.

In April 2022, Terumo will launch into the first year of its 5-Year Growth Strategy (GS26). The new strategy also highlights the need to realize an inclusive workplace environment. With the DE&I Philosophy in place, Terumo will further strive to fulfill the company’s purpose to advance healthcare and enhance patients’ quality of life.

*1 Revenue for FY2020 (April 2020 to March 2021): 613.8 billion yen / Japan: 201.8 billion yen / Outside of Japan: 412.0 billion yen
*2 Breakdown of associates by region: Japan 23.4% / Americas 42.8% / EMEA 8.8% / China 6.6% / APAC 18.4%

Additional Information

https://www.terumo.com/about/regulation/diversity-equity-inclusion/

DE&I Philosophy

Terumo is committed to cultivating a globally diverse, equitable and inclusive culture
DE&I Guiding Principle

At Terumo, we respect and value differences, and empower everyone to bring their authentic self to work, which leads to innovation that addresses the diverse healthcare needs of global society.

To promote Diversity, Equity and Inclusion (DE&I):

  • We commit to living our Core Values and our Code of Conduct.
  • We ingrain DE&I in our policies, processes and practices.
  • We do not tolerate words or actions that diminish DE&I such as discrimination, violence or hate.

 

TOKYO, JAPAN – May 14, 2021 – As the world joins together to fight the ongoing battle against the COVID-19 pandemic, Terumo Corporation (TSE: 4543) has announced that the Terumo Group companies will collectively donate USD 1 million in cash to support the COVID-19 Solidarity Response Fund for the World Health Organization (WHO). Terumo has already donated USD 1 Million in April 2020, and this is the company’s second time aiding the fund.

The fund, managed by the WHO Foundation, marked its first anniversary this March. So far, the donations collected from companies and individuals globally has supported WHO to mobilize nearly USD 250 million; into research for vaccines and tests, to share accurate scientific guidance to prevent infections, and to provide lifesaving supplies to those in need.

In addition to the current relief efforts, there is a new focused need for vaccine equity. Vaccine administrations have begun across the world, however low-income countries have received less than 1% of all of the vaccines administered worldwide. The new donation will aid WHO to contribute to vaccine equity broadly, and to other pressing needs for COVID-19 treatments, diagnostics, PPE distribution, and health system strengthening.

Shinjiro Sato, President and CEO of Terumo commented, “Healthcare is a fundamental human right, and as a medical device company we believe in equality of healthcare. We are honored to contribute to help those in need to get the necessary care and protection, and ultimately do what’s right for the world.”


About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.